The CDC recommends a single dose of any FDA-approved respiratory syncytial virus (RSV) vaccine for all adults ages 75 years ...

Q3 results confirms that the U.S. vaccine market for respiratory syncytial virus (RSV), led by Pfizer (PFE) and GSK (GSK), is ...

In June, the FDA expanded the approval of GSK's RSV vaccine (Arexvy) to include adults ages 50-59 at increased ... Changes to ...

While the U.S. Food and Drug Administration also approved this vaccine for people under 60, the Centers for Disease Control and Prevention (CDC) opted against recommending ... The newly approved ...

Image by Arek Socha from Pixabay November 12, 2024 - By Lorna Fernandes - As fall arrives, so does respiratory syncytial ...

CDC's Advisory Committee on Immunization Practices ... one by Pfizer called ABRYSVO that does not contain an adjuvant, and one by GSK called AREXVY that does. And the third RSV vaccine is by Moderna.

The CDC’s Advisory Committee on Immunization Practices ... flu vaccines if the shots are given together. GSK’s data with Arexvy, from the AReSVi-006 trial, appeared to show slightly higher ...

While outside the usual RSV season, Arexvy came in below forecasts ... could affect uptake in the US. Last year, the CDC recommended shots for those aged 60 and over after a physician consultation.

Regarding hospitalizations among immunocompetent older adults, vaccine effectiveness was 83% for the GSK vaccine and 73% for ...

GSK has claimed a new approval for its respiratory syncytial virus (RSV) vaccine Arexvy, currently locked in a battle for market share with rival shots from Pfizer and Moderna, that could lend it ...

In its update posted this morning, GSK revealed that sales of its Arexvy vaccine came in at £1.24 billion ($1.57 billion) in 2023, including £529 million ($671 million) from the fourth quarter.

The arrangement will run for three years in the first instance and, according to GSK, also “supports potential future co-development and commercialisation of Arexvy […] for adults 60 years and ...